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Abstract
Background: Protein Phosphatase 1 (PP1) is an enzyme essential to cell viability in the malaria parasite Plasmodium
falciparum (Pf). The activity of PP1 is regulated by the binding of regulatory subunits, of which there are up to 200
in humans, but only 3 have been so far reported for the parasite. To better understand the P. falciparum PP1
(PfPP1) regulatory network, we here report the use of three strategies to characterize the PfPP1 interactome:
co-affinity purified proteins identified by mass spectrometry, yeast two-hybrid (Y2H) screening and in silico
analysis of the P. falciparum predicted proteome.
Results: Co-affinity purification followed by MS analysis identified 6 PfPP1 interacting proteins (Pips) of which 3
contained the RVxF consensus binding, 2 with a Fxx[RK]x[RK] motif, also shown to be a PP1 binding motif and
one with both binding motifs. The Y2H screens identified 134 proteins of which 30 present the RVxF binding
motif and 20 have the Fxx[RK]x[RK] binding motif. The in silico screen of the Pf predicted proteome using a consensus
RVxF motif as template revealed the presence of 55 potential Pips. As further demonstration, 35 candidate proteins
were validated as PfPP1 interacting proteins in an ELISA-based assay.
Conclusions: To the best of our knowledge, this is the first study on PfPP1 interactome. The data reports several
conserved PP1 interacting proteins as well as a high number of specific interactors to PfPP1. Their analysis indicates a
high diversity of biological functions for PP1 in Plasmodium. Based on the present data and on an earlier study of the
Pf interactome, a potential implication of Pips in protein folding/proteolysis, transcription and pathogenicity networks is
proposed. The present work provides a starting point for further studies on the structural basis of these interactions
and their functions in P. falciparum.
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Background
Malaria continues to be a major health problem and a
leading cause of child mortality of the inter-tropical
regions despite extensive research efforts. The present
situation is also increasingly complicated by the emer-
gence of parasite resistance to multiple drugs much more
rapidly than the development of novel anti-malarials. A
major obstacle in devising new control tools is our lim-
ited knowledge of basic parasite biology and the paucity
of identified potential intervention targets. Plasmodium
species are obligate intracellular protozoan parasites
that undergo a number of developmental stages in the
vertebrate host and the invertebrate vector. During the
last decade, several studies strongly indicated that pro-
tein phosphorylation and dephosphorylation processes,
governed by kinases and phosphatases respectively, play
a central and essential role in Plasmodium cell cycle
and developmental regulation [1, 2].
In Plasmodium falciparum (Pf), the most deadly api-
complexan parasite, efforts have begun for an examination
of the biological roles of protein kinases and phosphatases
and their potential as drug targets. In this context, bio-
chemical and cloning studies have reported enzymatic
activities and the genes of catalytic subunits related to
plasmodial phosphatases. These include PfPP1c, PfPP2A,
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PfPP2B and PfPP2C, which have been shown to be highly
conserved during evolution, suggesting an essential role
for these enzymes [3–5]. With respect to the Pf Protein
Phosphatase type 1 catalytic subunit or PfPP1c, it cannot
be considered per se as a suitable drug target (> 80 % iden-
tity with human and yeast PP1 or GLC7). Indeed, comple-
mentation studies showed that PfPP1 was able to rescue
yeast mutated in PP1 [6]. In P. falciparum functional stud-
ies suggested that its activity predominates over the other
phosphatases in blood parasites [7]. Finally, phenotypic
PfPP1 gene knockdown and the use of phosphatase inhibi-
tors indicated that it seems to be essential for parasite
asexual development in erythrocytes [2, 4]. At this stage, it
is important to note that free PP1c seems to be toxic for
the cell [8] but a considerable number of proteins interact-
ing with PP1c have been reported that direct the
localization, specificity and the level of its activity in yeast
and higher eukaryotic cells [9]. Indeed, about 200 proteins
have been shown to physiologically interact with PP1c,
constituting a ‘PP1c platform’ that provides a framework
offering diverse functions to this enzyme in cell division,
transcription and apoptosis for instance [10]. Structural
and functional studies revealed that the interaction of reg-
ulators with PP1 involved several binding sites, including
mainly the so-called RVxF and SILK motifs [8, 11]. The
most studied binding motif is the RVxF for which it has
been established a first short consensus sequence as
[RK]x0-1[VI]{P}[FW] where x could be any amino acid and
{P} any amino acid except P [12].
The importance of these proteins in the regulation of
PP1 activity in vitro and in vivo prompted us to identify
the regulators of PfPP1c and to address their functions.
Our initial focus based on the completion of the Pf
genome and the delineation of known PP1 regulators
has revealed the existence of four conserved regulators.
So far, three gene products, Pf Leucine Rich Repeat 1
(PfLRR1), Pf Inhibitor 2 (PfI2) and Pf Inhibitor 3 (PfI3)
have been thoroughly explored to define their functions
in this parasite. Biochemical and structure-activity rela-
tionship studies demonstrated that these regulators
indeed bind to PfPP1. In these studies, we showed that
P. falciparum PP1 is submitted to a control of its activ-
ity by PfLRR1 (a homolog of yeast SDS22), Inhibitor-2
(PfI2) and -3 (PfI3) with substantial differences com-
pared to the human orthologs for Inhibitor 2 and 3
[13–18]. PfI2 exhibits an inhibitory role on PfPP1 activ-
ity, the short RVxF binding motif, not present in human
I2, a secondary Fxx[RK]x[RK] binding motif and a pep-
tide sequence 30 % shorter than its human homolog.
PfI3, although it contains the RVxF consensus motif,
does not seem to be an inhibitor but rather an activator
of PfPP1 in vitro and is unable to complement I3 defi-
cient yeast, suggesting a specific role for PfI3 on PfPP1.
In P. falciparum, our reverse genetic analyses suggest that
PfI2 as well as PfI3 are essential for parasite growth. Fur-
ther, NMR analysis showed that the main domain of PfI3
binding to PfPP1 is within residues P39-W45. The muta-
tion of the RVxF motifs in both proteins significantly
affects the binding to PP1. Finally, peptides derived from
these binding motifs have been shown to inhibit P. falcip-
arum growth in vitro [17, 18].
These observations underscore the importance of PP1
regulators and promote an increased interest to identify
P. falciparum PP1 interacting proteins (Pips). In the
present work, biochemical approaches, yeast two-hybrid
screens and in silico analysis were used to define the
Pips that are the starting point to elucidate PP1 inter-
action networks in P. falciparum and to provide new
pathways for further studies to reveal potential targets
for specific pharmacological intervention.
Results and discussion
Identification of Pips by affinity/Mass Spectrometry
In order to identify Pips expressed by P. falciparum,
affinity purification on PfPP1 followed by mass spec-
trometry was carried out. In this approach, soluble
extracts from blood stage parasites cleared as described
in Materials and Methods were incubated with PfPP1
covalently bound to sepharose beads. The eluate was
separated by SDS-PAGE and the proteins detected by
coomassie blue staining were identified by MS-MS. As
shown in Table 1, only 6 P. falciparum proteins were
clearly identified based on the number of peptides ana-
lysed and the corresponding mascot scores for each
protein (Additional file 1: Table S1). The identified pro-
teins, Ornithine aminotransferase, GAPDH and Phos-
phoethanolamine N-methyltransferase contained the
motifs KTVKF, KLVSW and RIIF respectively, which
comply with the RVxF consensus sequence, while
PfHSP90 and Pf disulfide isomerase have only one pu-
tative Fxx[RK]x[RK] motif (FENRKK and FNKKNK
respectively). Sequence analyses of PfHSP70 showed 2
potential binding motifs RLVNF and FKRKNR which
correspond to RVxF and Fxx[RK]x[RK] motifs respect-
ively, supporting a direct interaction. However, it could
not be excluded that this interaction may be related to
the chaperone functions of HSPs. Hence, it would be
necessary to further dissect the role of HSPs on the
function of PP1. Previous studies reported that PP1 in-
teracts with murine and human HSP70 [19, 20] which
are in agreement with the above data. Further, amino
acid sequence analysis of PfHSP70 showed 70 % identity
with mouse and human HSP70 and 2 potential binding
motifs, however only the binding motif Fxx[RK]x[RK] is
present in the latter (Additional file 2: Table S2). Overall,
the above approach led to the detection of a low number
of direct or indirect Pips when compared to the high
number of reported regulators/substrates of PP1c in other
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species. The low recovery by the affinity/mass spectrom-
etry analysis could be attributed to several factors includ-
ing the presence of very few free Pips in parasite extracts,
their low solubility in buffers suitable for affinity column
and/or the competition between Pips.
Yeast two hybrid screening of a Pf cDNA library
To further detect additional Pips in P. falciparum, a
cDNA library was screened in a yeast two hybrid (Y2H)
system using full-length PfPP1c as bait and clones
growing on high stringency selection media to reduce
the number of false positive clones. Five independent
screens yielded 189 clones from a total of 3.3 × 106
clones screened. After sequencing, all clones showed
open reading frames encoding Pf genes with 53 clones
in frame with GAL4AD and 136 clones out of frame.
Amino acid sequence comparison revealed that 8 pro-
teins in frame with GAL4AD were also found among
the out-of-frame clones. These data are in agreement
with an earlier observation indicating that out-of-frame
proteins could be considered as valid interactors in
Y2H screening [21] and with recent results suggesting
that translational frameshift could be means for yeast
to reduce the level of expression of exogenous proteins
in order to grow on selective media. Indeed, this was
observed with DHFR where most of isolated clones
were not in frame with GAL4AD. In addition, this work
showed that a reduction of growth rate of yeast was ob-
served when the screening was carried out with DHFR
fused in frame with GAL4AD [22]. Consequently, the
GAL4AD in frame and out-of-frame clones were in-
cluded in our analysis. In total, sequences identified
from 189 clones represented 134 different proteins (Table 2)
of which 27 were obtained more than once with 10 clones
for PF3D7_1202600 and 9 clones for PF3D7_0919900
(Additional file 3: Table S3). Analysis of the sequences re-
vealed that HSP70 (PF3D7_0818900) was isolated by Y2H
screens, reinforcing the idea of its interaction with PfPP1
that we observed using parasite extracts and a PfPP1 af-
finity column. This supports the interaction of HSP70
with PP1 and suggests that besides its chaperone func-
tion it may control PP1 activity and/or regulate its
binding with other partners. The Y2H screens also
identified the gene PF3D7_1020900 as a Pip. Its gene
product shares 72 % identity with a yeast ADP Ribosy-
lation Factor (ARF1) which has been shown to interact
with yeast PP1 [23] (Additional file 2: Table S2). Ana-
lysis of the Pf isolated fragment did not show the pres-
ence of known binding motifs to PP1. However the
analysis of the full length sequence revealed the pres-
ence of 1 RVxF motif, suggesting the presence of at
least 2 PfPP1 potential binding motifs in this protein.
Further, PF3D7_1103100 and PF3D7_1460700 showed
31 and 39 % of identity with yeast RPP1B and RPL27A
respectively (Additional file 2: Table S2), identified by dif-
ferent approaches as interactors of yeast PP1 [24, 25].
When the identified sequences were analyzed for the
presence of known binding motifs to PP1, 30 proteins
share the RVxF binding motif and 20 contain the
Fxx[RK]x[RK] motif, supporting the idea of their role
as potential regulators of PP1. Indeed, it was reported
that 70 % of PP1 interacting proteins containing the
RVxF motif are regulators of PP1 activity [26].
Further examination of Y2H screening revealed that
some identified clones correspond to different portions
of the same protein (16 clones representing 7 proteins).
For instance, PF3D7_1303800 interacts with PfPP1
through the protein portions 4987–5278, 6176–6407
(containing the Fxx[RK]x[RK] motif ) and 9165–9271
while PF3D7_0419900 binds PfPP1 via the portions
1857–1998 and 4414–4679 (Additional file 3: Table S3).
For these proteins it seems that their binding to PfPP1
could take place through at least 2 to 3 regions, poten-
tially involving novel binding motifs.
Among the isolated clones, 8 cDNAs representing 6
known kinases were identified as potential interacting
Table 1 Pips identified by affinity chromatography/mass spectrometry
Banda PlasmoDB Namec Motifs
(Position a.a.)dAccession numberb
1 PF3D7_0708400 heat shock protein 90 (HSP90) FENRKK (371–376)
2 PF3D7_0818900 heat shock protein 70 (HSP70) RLVNF (248–252)
FKRKNR (257–262)
3 PF3D7_0827900 protein disulfide isomerase (PDI8) FNKKNK (112–117)
4 PF3D7_0608800 ornithine aminotransferase (OAT) KTVKF (405–409)
5 PF3D7_1462800 glyceraldehyde-3-phosphate dehydrogenase (GAPDH) KLVSW (312–316)
6 PF3D7_1343000 phosphoethanolamine N-methyltransferase (PMT) KIIF (103–106)
aNumber of stained bands on SDS-PAGE
bAnnotations available on PlasmoDB database (v24)
cThe identified proteins were detected in 2 independent proteins extracts
dSequences complying with consensus of RVxF and Fxx[RK]x[RK] were indicated
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Table 2 Pips identified by Yeast two-hybrid screening
PlasmoDB Accession
numbera
Namea Growth on selective plates
(number of isolated clones)b
RVxF motifsc
In frame genes PF3D7_0107600 serine/threonine protein kinase, putative TDO/A (1)
PF3D7_0220000 liver stage antigen 3 (LSA3) QDO/A (2) KKVRF
PF3D7_0418300 conserved Plasmodium protein, unknown function QDO/A (1)
PF3D7_0520800 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_0520900 S-adenosyl-L-homocysteine hydrolase (SAHH) TDO/A (1)
PF3D7_0610100 Pre-mRNA-splicing factor SLU7, putative (SLU7) TDO/A (1)
PF3D7_0611800 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_0613800 transcription factor with AP2 domain(s) (ApiAP2) QDO/A (1) RGVYF
TDO/A (1)
PF3D7_0623100 nuclear polyadenylated RNA-binding protein NAB2, putative TDO/A (2)
PF3D7_0718100 exported serine/threonine protein kinase (EST) TDO/A (1)
PF3D7_0720700 phosphoinositide-binding protein, putative TDO/A (1) KIKF
PF3D7_0724600 protein kinase, putative TDO/A (1)
PF3D7_0803400 DNA repair protein rad54, putative QDO/A (1)
PF3D7_0816600 ClpB protein, putative (ClpB1) TDO/A (1)
PF3D7_0917900 heat shock protein 70 (HSP70-2) TDO/A (1)
PF3D7_0919900 regulator of chromosome condensation, putative QDO/A (8) KSVSF
PF3D7_1008000 histone deacetylase 2 (HDA2) TDO/A (1)
PF3D7_1008100 conserved Plasmodium protein, unknown function TDO/A (1) KSVSF
PF3D7_1020900 ADP-ribosylation factor (ARF1) TDO/A (1)
PF3D7_1031600 conserved Plasmodium protein, unknown function (GEXP15) QDO/A (3) KKVQF
PF3D7_1105100 histone H2B (H2B) TDO/A (1)
PF3D7_1130700 structural maintenance of chromosome protein, putative TDO/A (2)




PF3D7_1205500 zinc finger protein, putative TDO/A (1)
PF3D7_1228600 merozoite surface protein 9 (MSP9) TDO/A (1)
PF3D7_1229600 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_1303800 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_1317600 conserved Plasmodium protein, unknown function TDO/A (1) KYIYF
PF3D7_1325800 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_1346100 protein transport protein SEC61 subunit alpha (SEC61) TDO/A (1) KGIEF
PF3D7_1358200 conserved Plasmodium protein, unknown function TDO/A (1)
Out of frame
genes
mal_mito_2 cytochrome c oxidase subunit 1 (COX1) TDO/A (2)
PF3D7_0110200 FAD-linked sulfhydryl oxidase ERV1, putative (ERV1) TDO/A (1) KINF
PF3D7_0202400 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_0205700.1 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_0207100 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_0207500 serine repeat antigen 6 (SERA6) TDO/A (1)
PF3D7_0307700 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_0310400 parasite-infected erythrocyte surface protein (PIESP1) TDO/A (1)
PF3D7_0312800 60S ribosomal protein L26, putative TDO/A (1)
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Table 2 Pips identified by Yeast two-hybrid screening (Continued)
PF3D7_0317300 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_0319500 RNA binding protein, putative TDO/A (1)
PF3D7_0407700 conserved Plasmodium protein, unknown function TDO/A (1) RDIIF
PF3D7_0417400 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_0418000 conserved Plasmodium protein, unknown function TDO/A (2)
PF3D7_0418300 conserved Plasmodium protein, unknown function TDO/A (2)
PF3D7_0419900 phosphatidylinositol 4-kinase, putative QDO/A (2)
TDO/A (1)
PF3D7_0420000 zinc finger protein, putative TDO/A (1)
PF3D7_0509200 leucine-rich repeat protein (LRR2) QDO/A (1)
PF3D7_0516600 translation initiation factor IF-2 TDO/A (1)
PF3D7_0516900 60S ribosomal protein L2 (RPL2) TDO/A (1) KVIF
PF3D7_0520800 conserved Plasmodium protein, unknown function QDO/A (1)
PF3D7_0520900 S-adenosyl-L-homocysteine hydrolase (SAHH) TDO/A (1)
PF3D7_0525200 conserved Plasmodium protein, unknown function TDO/A (2) KIEF/KDVLF
PF3D7_0530000 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_0532100 early transcribed membrane protein 5 (ETRAMP5) TDO/A (2)
PF3D7_0602000 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_0604500 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_0611700 60S ribosomal protein L39 (RPL39) TDO/A (2)
PF3D7_0613800 transcription factor with AP2 domain(s) (ApiAP2) TDO/A (1)
PF3D7_0617200 conserved Plasmodium protein, unknown function QDO/A (1) KQIGF
PF3D7_0617800 histone H2A (H2A) QDO/A (2)
TDO/A (6)
PF3D7_0625300 DNA polymerase 1, putative TDO/A (1)
PF3D7_0709300 Cg2 protein (CG2) TDO/A (1) KVNF
PF3D7_0719900 conserved Plasmodium membrane protein, unknown
function
TDO/A (1)
PF3D7_0721100 conserved Plasmodium protein, unknown function QDO/A (1)
TDO/A (1)
PF3D7_0725300 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_0806900 conserved Plasmodium protein, unknown function QDO/A (1) KNIGF/KIRW
PF3D7_0809400 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_0811400 conserved protein, unknown function TDO/A (1)
PF3D7_0813200 CS domain protein, putative TDO/A (1)
PF3D7_0813300 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_0814000 60S ribosomal protein L13-2, putative QDO/A (2) RVNF
PF3D7_0815800 vacuolar sorting protein VPS9, putative TDO/A (1)
PF3D7_0818000 conserved protein, unknown function TDO/A (1)
PF3D7_0818900d heat shock protein 70 (HSP70) TDO/A (1)
PF3D7_0831700 heat shock protein 70, putative (HSP70-x) QDO/A (1)
PF3D7_0904000 GTPase-activating protein, putative TDO/A (1)
PF3D7_0919900 regulator of chromosome condensation, putative TDO/A (1)
PF3D7_0921700 conserved Plasmodium protein, unknown function QDO/A (1)
PF3D7_0924100 conserved Plasmodium protein, unknown function TDO/A (1)
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Table 2 Pips identified by Yeast two-hybrid screening (Continued)
PF3D7_0932100 protein MAM3, putative TDO/A (1)
PF3D7_0933300 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_1020200 conserved Plasmodium protein, unknown function TDO/A (1) KNVFF
PF3D7_1023400 HORMA domain protein, putative QDO/A (1)
PF3D7_1029900 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_1032000 ribosome maturation factor RimM, putative (RimM) TDO/A (1)
PF3D7_1103100 60S acidic ribosomal protein P1, putative (RPP1) TDO/A (1)
PF3D7_1105100 histone H2B (H2B) TDO/A (2)
PF3D7_1107300 polyadenylate-binding protein-interacting protein 1, putative
(PAIP1)
TDO/A (1)
PF3D7_1108600 endoplasmic reticulum-resident calcium binding protein
(ERC)
TDO/A (1) KVYF
PF3D7_1116200.1 pyridoxine biosynthesis protein PDX2 (PDX2) QDO/A (1)
PF3D7_1117700 GTP-binding nuclear protein ran/tc4 (RAN) QDO/A (1) RQIQF
PF3D7_1121600 circumsporozoite-related antigen,exported protein 1 (EXP1) TDO/A (1)
PF3D7_1127900 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_1141400 phosphatidylinositol N-acetylglucosaminyltransferase subunit
H, putative (PIGH)
TDO/A (1)
PF3D7_1149000 antigen 332, DBL-like protein (Pf332) TDO/A (1) KIIW
PF3D7_1206800 conserved Plasmodium protein, unknown function QDO/A (1)
PF3D7_1210600 conserved Plasmodium protein, unknown function QDO/A (1)
PF3D7_1211200 conserved Plasmodium protein, unknown function TDO/A (1) KVKF/KRINF/
KYIEF
PF3D7_1214100 GPI ethanolamine phosphate transferase 3, putative (PIGO) TDO/A (1)
PF3D7_1222300 endoplasmin, putative (GRP94) TDO/A (1)
PF3D7_1224000 GTP cyclohydrolase I (GCH1) TDO/A (1)
PF3D7_1227000 conserved Plasmodium protein, unknown function TDO/A (2)
PF3D7_1227700 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_1228600 merozoite surface protein 9 (MSP9) QDO/A (1)
TDO/A (1)
PF3D7_1229400 macrophage migration inhibitory factor (MIF) QDO/A (1)
TDO/A (1)
PF3D7_1231600 pre-mRNA-splicing factor ATP-dependent RNA helicase PRP2,
putative (PRP2)
TDO/A (1)
PF3D7_1234600 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_1234900 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_1240600 erythrocyte membrane protein 1, PfEMP1 (VAR) TDO/A (1)
PF3D7_1249800 THO complex subunit 2, putative (THO2) TDO/A (1)
PF3D7_1303800 conserved Plasmodium protein, unknown function TDO/A (2)
PF3D7_1306400 26S protease regulatory subunit 10B, putative (RPT4) TDO/A (1)
PF3D7_1308400 conserved Plasmodium protein, unknown function QDO/A (1) RRVLF
PF3D7_1308800 tyrosine recombinase (INT) QDO/A (1) KYIKF
TDO/A (1)
PF3D7_1316100 inositol polyphosphate kinase, putative (IPK2) TDO/A (1)
PF3D7_1324800 dihydrofolate synthase/folylpolyglutamate synthase
(DHFS-FPGS)
QDO/A (1)
PF3D7_1326600 conserved Plasmodium protein, unknown function QDO/A (2)
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proteins for PP1 but none of the fragments contains
any known binding motifs. This supports the idea that
these kinases encompass new PP1-binding region/mo-
tifs. Examination of the full length proteins of these 6
kinases showed the presence of at least one binding
motif (Additional file 3: Table S3). It would be import-
ant to check whether these motifs are also involved in
interaction with PP1. Taken together, it could be specu-
lated that these kinases could be direct substrates and/
or regulators of PfPP1 and vice versa.
In addition to the interaction of PfPP1 and kinases,
PfH2A, PfH2B and Pf Histone deacetylase 2 (PfHDA2)
have been identified as Pips. All of these proteins are as-
sociated with nucleosome modifications and could direct
the control of gene expression. Previous studies showed
that the phosphorylation marks of H2A and H2B are de-
tected along with lysine acetylation [27, 28]. The inter-
action of H2A and PP1 has also been reported in yeast
[24, 29] (Additional file 2: Table S2). Taken together,
these observations suggest a potential role and/or a con-
trol of the PP1 network in the marks of histones to gov-
ern diverse nuclear actions in P. falciparum.
Identification of Pips by in silico screening of the Pf
genome
PP1 partners have been identified by biochemical and
Y2H approaches, both of which can have their limita-
tions: the quality and quantity of protein preparations,
or the incapacity of yeast to produce Pf proteins (or
proteins toxic for the growth of yeast). In order to fur-
ther examine the presence of Pips genes in Pf, we used
an extended RVxF consensus sequence mentioned in
Materials and Methods. The choice of this extended
consensus sequence, referred thereafter as RVxFext, was
based on previous studies indicating its high specificity
[30, 31]. The first consensus sequence defined by
Table 2 Pips identified by Yeast two-hybrid screening (Continued)
PF3D7_1336600 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_1342300 tetratricopeptide repeat family protein, putative TDO/A (1)
PF3D7_1342900 transcription factor with AP2 domain(s) (ApiAP2) TDO/A (1)
PF3D7_1346400 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_1348400 conserved Plasmodium membrane protein, unknown
function
TDO/A (1)
PF3D7_1351200 conserved Plasmodium protein, unknown function TDO/A (1) KYVNW
PF3D7_1356900 protein kinase 5 (PK5) TDO/A (1)
PF3D7_1357400 conserved Plasmodium protein, unknown function QDO/A (1) KSIRF
PF3D7_1360700 E3 SUMO-protein ligase PIAS, putative (PIAS) QDO/A (1) KKVLW
PF3D7_1361200 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_1366400 rhoptry protein (Rhop148) TDO/A (1) KILF
PF3D7_1417600 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_1423700 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_1444300 1-acyl-sn-glycerol-3-phosphate acyltransferase, putative
(LPAAT)
TDO/A (1)
PF3D7_1456500 conserved Plasmodium protein, unknown function QDO/A (2)
PF3D7_1457000 signal peptide peptidase (SPP) QDO/A (1)
PF3D7_1460500 conserved Plasmodium protein, unknown function TDO/A (1) KVDF/KTVSF
PF3D7_1460700 60S ribosomal protein L27 (RPL27) TDO/A (1)
PF3D7_1464500 conserved Plasmodium membrane protein, unknown
function
TDO/A (1)
PF3D7_1465900 40S ribosomal protein S3, putative TDO/A (1)
PF3D7_1466300 26S proteasome regulatory subunit RPN2, putative (RPN2) TDO/A (1)
PF3D7_1470800 conserved Plasmodium protein, unknown function TDO/A (1)
PF3D7_1471900 conserved Plasmodium protein, unknown function TDO/A (1) KIIEF
aAnnotations available on PlasmoDB database (v24)
bSelection medium used for the growth of isolated yeast clones were indicated. Numbers indicate the count of isolated clones. TDO/A Triple dropout
supplemented with Aureobasidin A, QDO/A Quadruple dropout supplemented with Aureobasidin A
cThe presence and the sequence of RVxF binding motifs were indicated
dShared proteins isolated by affinity purification and Y2H screening
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Wakula et al. [12] was not used in this study because it
is less restrictive and it occurs randomly in ~25 % of all
proteins [30]. The bioinformatics analysis was per-
formed with ORFs present in PlasmoDB (v24). This
screening showed the presence of 55 RVxFext motif
containing proteins in P. falciparum of which 5 pro-
teins contain at least 2 motifs (Table 3). Two RVxFext
containing proteins were excluded as one corresponds
to a pseudogene and the second is annotated twice in
PlasmoDB. Interestingly, among the 55 in silico Pips, 42
exhibit at least one additional binding motif to PP1
(SILK and/or Fxx[RK]x[RK]) (Additional file 4: Table S4).
In addition, 8 proteins identified in silico were also iso-
lated by Y2H screening while 1 protein was common
between the affinity/MS-MS approach and Y2H screening
(Fig. 1). Among the 8 shared proteins, 6 clones identified
by Y2H screening followed the RVxFext consensus se-
quence. Further, homologs to 2 potential in silico PfPips
(PF3D7_1107700, PF3D7_1220100) have been shown to
interact with PP1 in S. cerevisiae (Additional file 2:
Table S2) [23, 32, 33]. The in silico screening applied in
this work cannot include PfLRR1 and Pf Inhibitors 2
and 3, known to bind and to regulate PfPP1 activity. In-
deed, PfLRR1 binds PP1 through LRR motifs, however
PfI2 and PfI3 encompass the short RVxF motif.
Validation of interaction of Pips identified
All interactors identified by the above approaches could
be capable of binding directly to PfPP1. To explore this
further, we decided to investigate the physical interaction
of PfPP1 with some of PfPips produced as recombinant
proteins. To this end, a binding assay with purified His-
tagged fusion Pips in E. coli and biotin labeled PfPP1
was used. This approach has already been used and vali-
dated using recombinant proteins of known partners of
PfPP1 or derived peptides from binding motifs [17]. PfI2
and PfI3, previously described to interact with PfPP1,
were used as positive controls. A total of 37 PfPips were
successfully produced as recombinant proteins in E. coli
and purified out of 68 candidates tested and correspond-
ing to 66 different Pips.
In the case of the Pips identified by PfPP1 affinity col-
umn, 5 proteins were produced out of 6. Binding data
presented in Fig. 2a showed that biotin-PfPP1 binds to
the 5 proteins tested. These data likely suggests that the
identified Pips are direct interactors of PfPP1.
Next, we searched to check the direct interactions of
Pips identified by Y2H screening and PfPP1. Fifteen re-
combinant PfPips were produced out of 30 cloned
cDNAs tested (Additional file 5: Figure S1, Additional
file 6: Table S5). The failure for the production of some
proteins could be due to the lack of expression and/or
to the toxicity for bacteria. For the binding with H2A
and H2B, commercially available human recombinant
proteins were used as they showed 67 and 63 % identity
with PfH2A and PfH2B respectively (Additional file 7:
Figure S2). As depicted in Fig. 2b, biotin-PfPP1 was able
to bind to 14 recombinant proteins out of 17 tested.
These data confirmed a direct interaction between PfPP1
and these Pips. Moreover, this binding assay showed that
Pips with or without the RVxF motif can bind PfPP1 and
confirmed that proteins which are out of frame of
GAL4AD could be true Pips. However, under the same
conditions, 3 proteins did not show significant binding
when compared to BSA. The lack of binding is unlikely
to be due to an absence of coating of purified protein to
wells as the quality of coating was checked using an anti-
His antibody (data not shown). It could be argued that
these proteins are not direct partners of PfPP1 or their
interaction may require additional partner(s) expressed by
the yeast.
Finally, in order to examine the binding capacity of
several in silico Pips identified by genome analysis, 32
fragments which correspond to 30 potential candidates
were tested for protein production. The fragments were
about 190 residues long with the RVxFext motif in the
middle of the recombinant proteins (Additional file 5:
Figure S1, Additional file 6: Table S5). The expression
and purification were successful for only 17 proteins.
Their ability to bind PP1 was then examined as described
above. Significant interactions for 16 out of 17 proteins
tested were observed (Fig. 2c). The lack of interaction of
PfPP1 with PF3D7_0305500 could be attributed to the fact
that its RVxF is not a valid binding motif. However, it is
important to point out that 6 Pips identified by Y2H and
in silico screens (PF3D7_0220000, PF3D7_0610100,
PF3D7_0919900, PF3D7_1008100, PF3D7_1031600 and
PF3D7_1202600) were confirmed to interact with PfPP1
by ELISA (Fig. 2b and c), highlighting the accuracy of the
RVxF consensus sequence used throughout this study.
To further explore the implication of the RVxF motifs
in PfPP1 binding, 2 Pips identified by Y2H screening
and in silico analysis were mutated in their RVxF motifs
and the corresponding recombinant proteins were pro-
duced. Results presented in Fig. 2d showed a significant
decrease of the binding with PfPP1 (about 86 % for
PF3D7_0220000 and 70 % for PF3D7_0919900). This
confirms that the RVxF motifs of these 2 Pips are the
main contributors for binding to PfPP1. However, it
could not be excluded that these interactions could in-
volve secondary structures of the protein to stabilize and
to lead to a functional complex. This could be attributed
to the fact that the RVxF binding motif, in most regula-
tors, is often present in intrinsically disordered regions
and the protein could adopt a structure upon binding
[16, 17].
The newly RVxF-containing PfPips were then used to
reexamine the features of the RVxF motif and the nature
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Table 3 Pips identified by genome in silico analysis
PlasmoDB Accession numbera Namea RVxFext motifsb
PF3D7_0204600 conserved Plasmodium protein, unknown function RKSVRW
PF3D7_0214400 conserved Plasmodium protein, unknown function KKKVTF
PF3D7_0220000c liver stage antigen 3 (LSA3) KKKVRF
PF3D7_0304300 conserved Plasmodium protein, unknown function KKKVTF
PF3D7_0305500 conserved Plasmodium protein, unknown function KRNVSF/KRSVHF
PF3D7_0323300 conserved protein, unknown function KKSVSF
PF3D7_0404700 dipeptidyl aminopeptidase 3 (DPAP3) RKNVTF
PF3D7_0407300 transcription factor, putative KKKVHF
PF3D7_0407700c conserved Plasmodium protein, unknown function KKKVSW
PF3D7_0416900 conserved Plasmodium protein, unknown function KRNVHF
PF3D7_0503000 50S ribosomal protein L28, apicoplast, putative RKNVRF
PF3D7_0513600 deoxyribodipyrimidine photo-lyase, putative KKQVSF
PF3D7_0526500 conserved Plasmodium protein, unknown function KKCVHF
PF3D7_0526600 conserved Plasmodium protein, unknown function KKKVTF
PF3D7_0610100c pre-mRNA-splicing factor SLU7, putative (SLU7) KKKVNF
PF3D7_0628100 HECT-domain (ubiquitin-transferase), putative RKSVKF/KKSVTF
PF3D7_0713900 conserved Plasmodium protein, unknown function KKNVNF
PF3D7_0717800 conserved Plasmodium protein, unknown function KRSVSW
PF3D7_0723800 conserved Plasmodium protein, unknown function KKSVQF
PF3D7_0727500 conserved Plasmodium protein, unknown function KKCVSF
PF3D7_0804500 conserved Plasmodium membrane protein, unknown function KKNVHF
PF3D7_0913600 conserved Plasmodium protein, unknown function KKMVHF
PF3D7_0917500 conserved Plasmodium protein, unknown function RKAVQF
PF3D7_0919900c regulator of chromosome condensation, putative KKSVSF
PF3D7_0922800 conserved Plasmodium protein, unknown function KKNVCF
PF3D7_0930100 conserved Plasmodium protein, unknown function KKTVHF
PF3D7_1002900 conserved Plasmodium protein, unknown function KRNVNF
PF3D7_1003700 conserved Plasmodium protein, unknown function KRKVKF
PF3D7_1008100c conserved Plasmodium protein, unknown function RKSVSF
PF3D7_1020600 conserved Plasmodium membrane protein, unknown function KKKVNW
PF3D7_1022200 conserved Plasmodium membrane protein, unknown function KKVVRF
PF3D7_1029400 conserved Plasmodium protein, unknown function KKNVSF
PF3D7_1031600c conserved Plasmodium protein, unknown function (GEXP15) KKKVQF
PF3D7_1107700 pescadillo-like protein (PES) KKKVTW
PF3D7_1106800 protein kinase, putative KKKVSF
PF3D7_1109100 conserved Plasmodium protein, unknown function RRKVSF
PF3D7_1113700 glyoxalase I (GloI) KKNVKF
PF3D7_1128000.1 conserved Plasmodium protein, unknown function KKNVTF
PF3D7_1139700 adrenodoxin reductase, putative RKKVHF
PF3D7_1200100 erythrocyte membrane protein 1, PfEMP1 (VAR) RKTVRF
PF3D7_1202600c conserved protein, unknown function KKNVTF/KKQVTF/
KRTVSF/KKSVSF/
KKTVSF/KKSVSF/KKNVSF
PF3D7_1220100 pre-mRNA splicing factor, putative KKMVNF
PF3D7_1234700 CPW-WPC family protein KKSVSF
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of the flanking amino acids in P. falciparum. The accepted
motif exhibits the sequence [K52R13][K55R10][K19N15S13T5]
V[S22H11T9R6Q6N6][F60W5] (Additional file 8: Figure S3).
Interestingly, the amino acids between V and F/W are
enriched by S and H (~50 %). At the N-terminal positions
of the RVxF (−1, and −2), the most conserved amino acid is
the K residue. We have also found a high frequency of L
residue at −2. Based on these data, the RVxF consensus




The identification in this study of 186 new Pips provides
new insights on the functional diversity of PfPP1 func-
tions. Among the 186 identified proteins, 108 (58 %)
have unknown function. For the 78 remaining proteins,
the most abundant proteins correspond to metabolism,
DNA maintenance, translation and phosphorylation pro-
cesses (Fig. 3).
Based on an earlier published P. falciparum interac-
tome [34] and on the identified PP1 interacting pro-
teins reported in this work, we were able to establish
three networks where several Pips could be involved.
The transcription and DNA maintenance network illus-
trated in Figure S4A (Additional file 9) contained 9
direct Pips (white circles) detected by the different ap-
proaches described above and 4 connecting proteins
(gray circles). The folding/proteolysis network involved
8 direct Pips and 2 connecting proteins (Additional file
9: Figure S4B). The pathogenicity network comprised
18 direct Pips and 16 connecting proteins (Fig. 4). In
the latter network, 2 homologs of direct Pips in P. ber-
ghei (PBANKA_0408500 homolog to PF3D7_0310400
and PBANKA_0926700 homolog to PF3D7_1121600)
have been shown to be essential for parasite survival as
no viable KO parasites can be obtained [35, 36]. It is
worthy of note that PF3D7_1023900, a connecting pro-
tein, contains a region of about 700 amino acids with
40 % identity with a yeast protein (YER164W) which
has been shown to interact with yeast PP1 [23]. Its
homolog in P. berghei (PBANKA_050810) has been
shown to be essential for parasite survival [35]. The
network analysis raises the possibility that new Pips
Table 3 Pips identified by genome in silico analysis (Continued)
PF3D7_1238500 conserved Plasmodium protein, unknown function KKKVHF
PF3D7_1244200 transcription factor Tfb2, putative RKSVHF
PF3D7_1244500 conserved Plasmodium protein, unknown function RRKVNF
PF3D7_1322100 variant-silencing SET protein (SETvs) KRNVSF
PF3D7_1364300 pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16 (PRP16) RKMVQF
PF3D7_1366300 conserved Plasmodium protein, unknown function KKVVKF/KKKVQF
PF3D7_1367500 NADH-cytochrome b5 reductase, putative KKHVHF
PF3D7_1406200 conserved Plasmodium protein, unknown function KKMVSF
PF3D7_1411500 conserved Plasmodium protein, unknown function KKQVSF/KKKVSF
PF3D7_1413000 conserved Plasmodium protein, unknown function KKNVQF
PF3D7_1417300 cysteine protease ATG4, putative (ATG4) KKKVRF
PF3D7_1460500c conserved Plasmodium protein, unknown function RKTVSF
aAnnotations from PlasmoDB database (v24)
bThe RVxFext binding motifs corresponding to the [KR][KR][ACHKMNQRSTV]V[CHKNQRST][FW] consensus sequence were indicated
cShared proteins isolated by Y2H and in silico screenings
Fig. 1 Venn diagram. Graphic shows the distribution of identified
Pips by the three approaches
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could play a role in pathogenicity, at least in part,
through their interaction with and regulation of PfPP1.
However, it cannot be excluded that these proteins
could be also substrates of PfPP1.
Conclusion
The diversity of proteins identified by three different and
complementary approaches suggests that PP1c has a
wide interaction network which controls several aspects
of parasite physiology. A total of 186 proteins were iden-
tified by these approaches. One protein was common to
both Y2H screening and PfPP1-affinity column approach
and 8 proteins to Y2H and in silico screenings. This pro-
vides experimental support to determine the contribu-
tion of the RVxF motif to PfPP1 binding when present
in Pips, to identify new binding regions/motifs specific
of Plasmodium and to explore the role of Pips as regula-
tors, substrates or both. Further experiments need to be
done to determine PfPP1 substrates, for instance by
identifying the phosphoproteomes of Pf in vitro in the
absence and presence of recombinant active PfPP1, and
to evaluate whether the new Pips could be able to regu-
late PfPP1 activity. These future studies will help to
better elucidate PP1 signaling in Plasmodium and to in-
crease and improve the choice of parasite targets for
drug design.
Methods
Affinity purification of Pips
For affinity purification, 10 mg of PfPP1 recombinant
protein (produced as previously described [17]) were co-
valently coupled to 0.5 ml of CNBr-activated Sepharose
4B according to the supplier’s instructions (Sigma). The
coupling efficiency was > 90 %. Before use, PP1 beads
were submitted to 3 wash cycles with 3 M NaSCN and
PBS. Ten mg of total soluble parasite extract (prepared
as previously described [17]) were precleared on 2 ml of
activated sepharose beads blocked with ethanolamine.
The precleared extract recovered by centrifugation was
filtered, divided in 2 equal volumes and incubated with
Fig. 2 Direct interaction of Pips to PfPP1. The binding capacity of recombinant Pips (25pmol/well) to biotin-PfPP1 (4pmol/well) was measured
using an ELISA-based assay. a represents the binding of recombinant Pips identified by PP1-affinity column (gray bars). PfI2 (PF3D7_0320000) and
PfI3 (PF3D7_1031700) were used as positive controls (white bars) and BSA was used as negative control (black bars). b represents the binding of
Pips identified by Y2H screening (gray bars). AAN59960 and AAN59961 are human H2A and H2B proteins respectively which present high identity
with PfH2A (PF3D7_0617800) and PfH2B (PF3D7_1105100). c represents the Pips identified by genome in silico analysis (gray bars). d contribution
of the RVxF motifs to the binding of PF3D7_0220000 and PF3D7_0919900 to PfPP1 (gray bars). The interaction of PfPP1 to wild proteins was
considered at 100 % binding. Results are presented as mean ± SD of 2 independent experiments preformed in duplicate. *p < 0.05, **p < 0.01
and ***p < 0.001 (Mann–Whitney U test), compared to the negative control
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Fig. 4 PfPP1 Pathogenicity network. The graph shows interactions (lines) between Pips identified by our different approaches (white circles) and
PfPP1 (square box). The gray circles represent connecting proteins based on the results of Lacount et al. [34]. When available, gene names given
in PlasmoDB are shown in brackets
Fig. 3 Pie chart of biological functions of Pips. A total of 186 proteins are classified in 12 different biological functions based on confirmed or
putative functions indicated in PlasmoDB and shown in our pie chart
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BSA-sepharose beads or PP1-beads overnight at 4 °C.
After 5 washings with 50 mM Tris, 0.3 M NaCl, proteins
were eluted with 2 × 0.5 ml of 3 M NaSCN. The proteins
were then precipitated with acetone and separated on
SDS-PAGE. No stained bands were observed for eluates
of BSA-sepharose beads. Stained bands observed for elu-
ates of PP1 column affinity were cut for MS/MS identifi-
cation as previously described [37].
Plasmid and yeast strain
The cDNA library of Plasmodium falciparum, cloned
in pGAD-HA vector, was purchased from Dualsystems
Biotech. In this plasmid, the expressed parasite pro-
teins are fused to the GAL4 activation domain. Yeast
Y2HGold strain (Clontech) was transformed with the
pGAD-cDNA library according to the method for high-
efficiency library scale transformation of Dualsystems
Biotech, and allowed to form colonies on 150 mm
plates with SD agar medium lacking leucine (SD/-Leu)
at 30 °C (3-4 days). Y2HGold contains four integrated
reporter genes (AUR1-C, HIS3, ADE2 and MEL1)
under the control of three distinct GAL4 responsive
promoters used to detect two-hybrid interaction and in
order to reduce false positives. All clones were scraped,
harvested with a freezing medium (YPDA medium with
25 % glycerol) and stored in 1 ml aliquots at −80 °C for
further experiments. This library-transformed yeast
strain is referred below as the prey strain.
The cDNA encoding for P. falciparum protein phos-
phatase type-1 (PfPP1, PlasmoDB accession number:
PF3D7_1414400) was cloned in the pGBKT7 vector
(Clontech) to generate a PfPP1-pGBKT7 plasmid allow-
ing the production of PfPP1 fused with the GAL4 DNA
binding domain. Y187 yeast competent cells (Clontech)
were then transformed with this construct according to
the manual of Yeastmaker™ Yeast Transformation Sys-
tem 2 (Clontech). The expression of PfPP1 was checked
by immunoblot using anti-GAL4BD antibody. This
strain was used as a bait to screen protein interactions
with the P. falciparum cDNA library by mating.
Yeast two-hybrid assay
All reagents and methods for yeast-two hybrid assays
were from the Matchmaker™ Gold Yeast Two-Hybrid
System (Clontech).
One fresh and large colony of bait yeast strain
(pGBKT7-PfPP1 in Y187) was inoculated into 50 ml of
SD/-Trp/Kan (Kanamycin) liquid medium agitated at
250 rpm, 30 °C until the OD600 reached 0.8. The
supernatant was discarded after centrifugation for
5 min at 1,000 g. The pellet was suspended in 5 ml of
SD/-Trp/Kan liquid medium ([cells] >1 × 108/ml). 1 ml
of library prey strain (after rechecking the titer) and
5 ml of bait strain Y187 were combined with 45 ml of
2xYPDA liquid medium and incubated for 20–24 h at
30 °C at 40 rpm. The culture was centrifuged for
10 min at 1,000 g, then 50 ml of 0.5xYPDA liquid
medium (with 50 μg/ml Kan) was added to resuspend
the pellet. After a centrifugation for 10 min, cells were
suspended in 10 ml of 0.5xYPDA liquid medium (with
50 μg/ml Kan) and the total volume was measured. To
calculate the number of screened clones and the mating
efficiency, 100 μl of the fusion culture (diluted by 101
gradient) were plated on the selective medium SD/-Trp,
SD/-Leu, and SD/-Trp/-Leu (Double dropout medium,
DDO) and incubated for 3–5 days at 30 °C. More than
1 million diploids were screened to maximize chances
of detecting genuine interactions on Aureobasidin A
(AbA) plates. The remaining fusion culture was spread
onto selective medium SD/-Trp/-Leu/Kan supple-
mented with 125 ng/ml AbA (DDO/A), 200 μl per
150 mm plates and incubated for 3–7 days at 30 °C.
Colonies obtained were re-streaked onto higher stringency
SD/-Trp/-Leu/-His/AbA/Kan (TDO/A, Triple dropout
supplemented with AbA) and SD/-Trp/-Leu/-His/-Ade/
AbA/Kan (QDO/A, Quadruple dropout supplemented
with AbA) agar plates. This screening was carried out five
times independently.
Identification of potential Pips
The prey plasmids from positive yeast clones were isolated
using the Plasmid DNA Purification kit (Macherey-Nagel).
To facilitate yeast lysis, the equivalent of 100 μl of glass
beads (Sigma) was added in the resuspension buffer. To
amplify the plasmid obtained, it was transformed to E. coli
DH5α cells (Life Technologies) followed by selection on
LB/Ampicillin and LB/Kanamycin plates. Plasmids were
isolated once again using the Plasmid DNA Purification
kit and then to estimate the sizes of the specific inserts on
positive prey plasmids, plasmids were digested using the
SfiI restriction enzyme.
The positive prey plasmids were characterized by se-
quencing and BLAST searches to identify the correspond-
ing P. falciparum genes in the PlasmoDB database (v24).
In silico screening
The consensus sequence used to identify potential inter-
actors of PfPP1, was [KR][KR][ACHKMNQRSTV]V
[CHKNQRST][FW]. It was based on the crystal of PP1
with a RRVSFA peptide [38] and on consensus se-
quences defined by different publications [12, 30, 31].
After identification of the putative partners, the posi-
tions −10 to +10 of RVxF motifs were aligned by BioEdit
software (v7.2.5) to establish a new consensus sequence.
Recombinant proteins expression and purification
In order to verify the interaction between PfPP1 and its
new interactors, His-tagged recombinant proteins were
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produced. Concerning Pips from Y2H screening, the
recombinant proteins correspond to the fragment iden-
tified during the screening (Additional file 6: Table S5). For
Pips from in silico screening, the A/T rich regions or
acidic amino acids were eliminatory to avoid a lack of
expression in E.coli. The different RVxF motifs were
placed in the middle of recombinant proteins. The
chosen coding regions for Pips were obtained by PCR
with the primers mentioned in Additional file 10: Table
S6 using the Advantage 2 Polymerase Mix (Clontech).
The PCR conditions consisted of 10 min at 94 °C
followed by 35 cycles at 94 °C (45 s), 56 °C or 58 °C
(1 min) and 68 °C (1 min 30), finished by 7 min at 68 °C.
To examine the role of RVxF binding motif, mutated
constructs (KSVSF to KSASA for PF3D7_0919900,
and the introduction of a stop in the second position
of the KKVRF motif for PF3D7_0220000) were ob-
tained by a PCR-based site-directed mutagenesis ap-
proach using the wild pQE30-PF3D7_0919900 and
pETDuet-PF3D7_0220000 constructions as templates,
the primers mentioned in Additional file 10: Table S6
and Isis DNA polymerase (MP Biomedicals). The mu-
tations were checked by sequencing.
For the expression of Pips, the pETDuet-1 (Novagen)
or pQE30 (Qiagen) expression system and the In-Fusion
HD Cloning system (Clontech) were used according to
the supplier’s instructions. The plasmids and restriction
sites are mentioned in Additional file 10: Table S6. The
constructions obtained were checked by sequencing and
transformed in One Shot® BL21 Star™ (DE3) Chemically
Competent E. coli cells (Life Technologies) for expression.
The expression of His6-Pips was carried out in the
presence of 0.5 mM IPTG at 37 °C for 2 h. Cells were
harvested in sonication buffer (20 mM Tris, 500 mM
NaCl, 6 M Guanidine, 20 mM Imidazole and protease
inhibitor cocktail (Roche), pH 7.5). Recombinant pro-
teins were purified according to manufacturer’s in-
structions by Ni2+-NTA agarose beads (Macherey
Nagel). Washing steps were performed with a buffer
containing 20 mM Tris, 500 mM NaCl and 20 mM
imidazole, pH 7.5. Elution was done with a buffer con-
taining 20 mM Tris, 500 mM NaCl and 600 mM imid-
azole, pH 7.5. The eluted proteins were dialyzed
against 20 mM Tris, 500 mM NaCl, pH 7.5.
PfPP1 was produced as described above [16] with a
dialysis buffer containing 20 mM Tris, 500 mM Nacl
and 1 mM MnCl2, pH 7.5.
The produced proteins were quantified with the
Pierce™ BCA Protein Assay Kit (Life Technologies) and
checked by western blot. Soluble proteins were sepa-
rated on a 4–20 % SDS-PAGE and subsequently blotted
onto nitrocellulose. The blots were probed with anti-
His antibody (1:2000 dilution) (Qiagen). As secondary
antibody, a horseradish peroxidase-labeled anti-mouse
IgG (1:20000 dilution) was used, followed by chemilu-
minescence detection with SuperSignal™ West Dura Ex-
tended Duration Substrate (Life Technologies).
Measurement of Pips binding
Binding of Pips to PfPP1 was assessed by an ELISA-
based assay as previously described [17]. The plates
were coated with 25pmol of each Pips in PBS overnight
at 4 °C. In these experiments, recombinant PfI2 and
PfI3 [16, 17] and BSA were used as positive and nega-
tive controls respectively. The statistical significance
was calculated with the Mann-Whitney U test for non-
parametric data and p < 0.05 was considered significant.
Bioinformatic analysis
The different binding motifs were identified using the
tool “Protein Motif Pattern” available on PlasmoDB web-
site. For biological functions of Pips, only the putative or
characterized functions were taken into account. The
GO annotation of unknown proteins was not retained.
For functional analysis, the different protein subnet-
works were based on the results from LaCount [34] and
our interactions with PfPP1. After manual correction,
they were visualized on Cytoscape (v3.2.1). The Venn
diagram was established from Venny [39].
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